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Tumour associated neovascularisation has been charac-
terised as chaotic and insufficient. This report details the
results of the analysis of angiogenic factors in tumour cyst
fluid, pleural fluid, and blood from a patient with a
gastrointestinal autonomic nerve tumour. The tumour pro-
duced vascular endothelial growth factor and endostatin in
large quantities, which may explain the dysfunctional
angiogenesis and tendency to bleeding seen in this tumour
type.
T
he gastrointestinal autonomic nerve tumour (GANT) was
first described in 1984 by Herrera as a subtype of gastro-
intestinal stromal tumours.1 These tumours are thought
to arise from the interstitial cells of Cajal. They are composed
of spindle shaped cells with eosinophylic fibrillary cytoplasm
arranged in a fascicular or palisaded pattern and with ovoid
nuclei. In the stroma there is often microcytic degeneration
and lymphocytic infiltration. The cells commonly express
CD117 (c-kit) and CD34, in addition to neurone specific
enolase (NSE) and S-100.2 GANTs commonly arise along the
gastrointestinal tract and metastasise to the liver and neigh-
bouring structures. A striking vascularity has been men-
tioned, associated with cysts filled with blood and bleeding as
a presenting symptom. This suggests active but dysfunctional
neovascularisation. Therefore, proteins involved in angiogen-
esis are of interest, including vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF), pro-
teases, and endostatin. VEGF and bFGF have been shown to
stimulate endothelial proliferation and migration in vitro,
and tumour growth and metastasis in vivo.3 4 Matrix
metalloproteases (MMPs) and proteases from the plasmino-
gen activator family (PAs) are thought to be essential for the
degradation of the extracellular matrix, thereby allowing the
invasion and migration of cells.5 Endostatin, a 20 kDa C-
terminal domain of collagen XVIII, a collagen that is present
in basement membranes,6 inhibits the growth and migration
of endothelial cells in vitro, in addition to the growth of
tumours and their metastases in vivo.7
In this case report, we explored the angiogenic process,
reflected by VEGF, bFGF, endostatin, and various proteases
in tumour fluid, pleural fluid, and blood from a patient with a
GANT.
CASE REPORT
In 1993, a 24 year old woman underwent a laparotomy
because of bleeding in the liver. A hemi-hepatectomy was
performed and revealed a tumour of 11 6 15 cm; in addition
a 3 cm tumour was resected from the ileum. The tumours
were diagnosed as GANT. In 1998, surgery was performed
because of multiple GANT lesions in the pelvis. In May 2001,
tumour cyst fluid was taken from a liver lesion and pleural
fluid during an episode of pleurodesis. In 2002, the patient
died because of bleeding in a lung metastasis.
MATERIAL AND METHODS
Sections (4 mm thick) were cut from formalin fixed, paraffin
wax embedded sections and mounted on Superfrost Plus
slides (Menzel, Germany), dried overnight, dewaxed, and
dehydrated. Next, antigen retrieval was performed with
10mM citrate buffer (pH 6.0) at 100 C˚ in a microwave oven,
pretreatment was performed with either trypsin or pepsin in
the Nexes IHC automated immunostainer (Ventana,
Strassburg, France). Endogenous peroxidase activity was
blocked with 0.03% hydrogen peroxide in methanol for 10
minutes. Slides were stained either by hand or in the
automated immunostainer according to the manufacturer’s
instructions (Ventana). Slides were washed with phosphate
buffered saline between steps. Visualisation was performed
with either diaminobenzidine or envision kit; subsequently,
the slides were counterstained with haematoxylin, dehy-
drated, and mounted in DePeX mounting medium (BDH
Laboratory Supplies, Poole, Dorset, UK). CD34, mouse
monoclonal (ms-mono), CD117 (ms-mono), chromogranin
(ms-mono), anti-NSE (ms-mono), anti-S-100 (rabbit poly-
clonal), K6, and K20 (ms-mono) were purchased from Dako
(Ely, Cambridgeshire, UK). The antibody to vimentin (ms-
mono) was a gift from Dr J Hilgers (Department of
Gynaecology, VUMC, Amsterdam, the Netherlands).
For electron microscopy, fragments of the tumour were
fixed in 2% glutaraldehyde, postfixed in osmium tetraoxide,
dehydrated with ethanol, and embedded in Epon. Ultrathin
sections were collected on Formavar coated copper grids. The
sections were contrasted with uranyl acetate and lead citrate
and examined in a JEOL 1200 EX electron microscope.
The VEGF and bFGF enzyme linked immunosorbent assay
(ELISA) kits were from R&D Systems (Minneapolis,
Minnesota, USA) and the endostatin ELISA was from
Cytimmune (College Park, Maryland, USA).
The MMP-2 and MMP-9 activity assays were from
Amersham Biosciences (Cardiff, UK). These assays separately
measure active and total (active plus latent) activity. Protein
concentrations of MMP-2 and MMP-9 were measured with a
standard quantitative ELISA, as described previously.8 The
urokinase PA (uPA) protein concentration was measured by
means of the immunoassay kit: u-PA EIA HS (Taurus,
Leiden, the Netherlands). The activity of uPA and plasmin
was determined as described previously.9 The tissue PA (tPA)
Abbreviations: bFGF, basic fibroblast growth factor; ELISA, enzyme
linked immunosorbent assay; GANT, gastrointestinal autonomic nerve
tumour; MMP, matrix metalloprotease; ms-mono, mouse monoclonal
antibody; NSE, neurone specific enolase; PS, plasminogen activator;
STS, soft tissue sarcomas; tPA, tissue plasminogen activator; uPA,
urokinase plasminogen activator; VEGF, vascular endothelial growth
factor
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antigen was determined using a specific tPA ELISA (Biopool
Int, Umea, Sweden).
RESULTS
Histopathology revealed a mesenchymal proliferation, nega-
tive for keratins, and with focal positivity for c-kit and CD34.
Vimentin, S-100, NSE, and chromogranin were positive.
Eleven mitoses/2 mm2 were found. The vascularisation of the
tumour tissue was exuberant. VEGF was expressed abun-
dantly in this tumour and large cysts with VEGF positivity
were present (fig 1).
Electron microscopic examination revealed the focal
accumulation of desmosomes in the tumour cells. Dense
core granules were seen in the cytoplasm of the tumour cells
and microtubules were present focally. Intercellular skeinoid
fibres were absent but collagen fibres, approximately 20 nm
thick, were seen.
Tables 1 and 2 show data from the patient’s tumour fluid,
pleural fluid, and blood. There were high concentrations of
both VEGF and endostatin in all three sample types. The
production and activity of MMP-2, MMP-9, and uPA was
reduced in tumour fluid. The concentration of tPA and the
activity of plasmin were higher than those seen in tumour
fluid from nine other patients with sarcoma.
DISCUSSION
GANTs are associated with bleeding, haemorrhagic cysts, and
a high vascularity,1 2 as was the case in our patient. Large
intratumoral cysts have been described as a frequent
characteristic of soft tissue sarcomas (STS) in general, and
these cysts often contain high amounts of VEGF,10 which is a
permeability factor also. The concentration of VEGF, but not
of bFGF, was extremely high in tumour fluid, pleural fluid,
and in serum from our patient.
A remarkable finding was the increased concentration of
endostatin in tumour fluid, pleural fluid, and plasma of our
patient. This is an unusual finding because the concentration
of endostatin in the tumour fluid from nine other STS was
not different from the normal plasma value, and the
concentrations of endostatin in pleural fluid and ascites
were also not increased in a series of 92 samples from a broad
spectrum of cancer types.11 This finding suggests that this
GANT tumour generated (an) enzyme(s) capable of degrad-
ing CXVIII to endostatin. Increased serum concentrations of
endostatin in patients with STS, associated with an increased
risk of tumour recurrence after resection, have been reported
previously.12 The role of endostatin in the biology of these
tumours warrants further study.
‘‘A remarkable finding was the increased concentration of
endostatin in tumour fluid, pleural fluid, and plasma of our
patient’’
Mechanistic studies have not yet firmly established a
unique receptor or target for endostatin. Binding to cell
surface integrins (a5b1), blocking the VEGF–KDR/Flk-1
interaction, and binding the catalytic domain of MMP-2
have been suggested.13–15 In the tumour fluid of our patient,
the activity of MMP and uPA was reduced, but the tPA
protein concentration and plasmin activity were greatly
increased, which is in accordance with the mechanism of
action suggested by Reijerkerk et al.16 These workers
suggested that VEGF induces hyperpermeability of vessels,
resulting in the local influx of plasma proteins and the
generation of a fibrin containing ‘‘provisional matrix’’, which
facilitates the migration of endothelial cells. However,
excessive degradation of this matrix by increased plasmin
activity may have largely contributed to a high turnover of
blood vessels and the bleeding tendency in this tumour.
In the case reported here, increased production of VEGF
was accompanied by the generation of endostatin. Because
VEGF initiates angiogenesis, resulting in the generation of
immature vessels, and endostatin inhibits angiogenesis,
Figure 1 Immunohistochemical staining for vascular endothelial growth
factor showing pseudocyst formation with positively (brown) stained cyst
fluid, and positive tumour cells surrounding the cyst (original
magnification,610).
Table 1 Angiogenic proteins in tumour fluid
Patient
9 other STS patients
Median Range
VEGF (pg/ml) 7026 15529 698–51 425
bFGF (pg/ml) 5.4 4 0.8–941
Endostatin (ng/ml) 371 26 10–65
MMP-2
Active (U/ml) 0 0 0
Total (U/ml) 705 1190 820–9440
Protein (ng/ml) 907 1550 818–4433
MMP-9
Active (U/ml) 60 115 0–1715
Total (U/ml) 520 1840 410–17090
Protein (ng/ml) 78 160 113–160
uPA
Active (U/ml) 5270 10835 8010–19930
Total (U/ml) 5525 13235 9010–22975
Protein (ng/ml) 7 42 4–124
tPA (ng/ml) 370 18 3–1418
Plasmin (U/ml) 25880 4600 0–16120
Normal values: VEGF in plasma, ,55 pg/ml, in serum 200–300 pg/ml;
bFGF in plasma/serum, ,6.9 pg/ml; endostatin in plasma/serum, 20–
25 ng/ml.
bFGF, basic fibroblast growth factor; MMP, matrix metalloprotease; STS,
soft tissue sarcomas; tPA, tissue plasminogen activator; uPA, urokinase
plasminogen activator; VEGF, vascular endothelial growth factor.
Table 2 Angiogenic proteins in plasma, serum, and
pleural fluid (PF)
PF Plasma Serum
VEGF (pg/ml) 2239 80 1540
bFGF (pg/ml) 1.5 1.9 3.0
Endostatin (ng/ml) 106 45 40
Normal values: VEGF in plasma, ,55 pg/ml, in serum 200–300 pg/ml;
bFGF in plasma/serum, ,6.9 pg/ml; endostatin in plasma/serum, 20–
25 ng/ml.
bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth
factor.
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ultimately resulting in apoptosis of immature vessels, this
combination might have had a negative effect on the
integrity of the endothelial lining. Tumour associated
neovascularisation has been described as an active, but
abnormal and inefficient process, because of the absence of a
balanced angiogenesis programme. In this GANT the
presence of both VEGF and endostatin could have led to
dysfunctional angiogenesis. It remains to be determined
whether other GANTs have this angiogenic profile and
whether this can explain the relatively mild progression of
this disease and bleeding as a complication.
This is the first description of a tumour producing both the
angiogenesis stimulator VEGF and the angiogenesis inhibitor
endostatin. The investigation of tumour fluid, which can be
seen as the in vivo ‘‘conditioned medium’’ of a tumour, was
of great help in understanding the dysfunctional vascularisa-
tion of this tumour.
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Take home messages
N We analysed angiogenic factors in the tumour cyst
fluid, pleural fluid, and blood of a patient with a
gastrointestinal autonomic nerve tumour and found
that large quantities of both vascular endothelial
growth factor (VEGF) and endostatin were present
N This is the first description of a tumour producing both
the angiogenesis stimulator VEGF and the angiogen-
esis inhibitor endostatin
N This may explain the dysfunctional angiogenesis and
tendency to bleeding seen in this tumour type
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